Restrictive Lung Disease
Pirfenidone May Be Effective for Improving Exercise Capacity, Dyspnea in Idiopathic Pulmonary FibrosisOctober 10, 2018
When treated with pirfenidone, patients with idiopathic pulmonary fibrosis experienced significant improvements in 6-minute walking distance and University of California San Diego Shortness of Breath Questionnaire scores.
Blacks experience a significantly higher rate of sarcoidosis-associated hospitalizations compared with whites.
Health-related quality of life and isolated exertional hypoxia in patients with interstitial lung disease may be improved by the use of ambulatory oxygen.
The primary objective was to characterize the long-term safety and tolerability of Ofev in patients with IPF; efficacy endpoints included annual rate of decline in forced vital capacity (FVC) calculated over 192 weeks.
Nintedanib plus sildenafil did not improve St. George's Respiratory Questionnaire scores in patients with idiopathic pulmonary fibrosis.
Although gastroesophageal reflux disease and idiopathic pulmonary fibrosis may be related, the association between the 2 disorders is most likely confounded by smoking.
The FDA's designation was based on data from a Phase 2 placebo-controlled trial that demonstrated pamrevlumab could potentially address an unmet medical need for this condition.
Laparoscopic antireflux surgery was safe and well tolerated in patients with idiopathic pulmonary fibrosis and abnormal acid gastroesophageal reflux.
Adding routine rheumatologic assessments to interstitial lung disease diagnosis could reduce the need for invasive procedures and improve diagnostic accuracy.
Rituximab is a safe and effective alternative to cyclophosphamide in managing the progression of scleroderma and subsequent development of interstitial lung disease.
Targeting TGF-β signaling in a tissue-specific manner allows the drug to modulate the fibrotic cascade with maximum clinical effects while avoiding adverse events.
An expert panel developed suggestions for chronic cough management in interstitial lung disease, but more clinical trials are needed to establish recommendations.
Many patients with idiopathic pulmonary fibrosis in an international phase 4 study tolerated combination therapy with pirfenidone and nintedanib.
Compared with individuals who had stable idiopathic pulmonary fibrosis, those with an acute exacerbation had a significantly shorter survival, especially at the 3 year follow-up.
Low nailfold capillary density is associated with impaired pulmonary function tests and more frequent high-resolution computed tomography abnormalities in patients with juvenile dermatomyositis.
In patients with end-stage interstitial lung disease, there was a higher rate of survival to transplantation with venoarterial extracorporeal membrane oxygenation.
Double lung transplantation appears to offer superior survival outcomes to single lung transplantation in patients with interstitial pulmonary fibrosis who are younger than 70 years.
Recombinant human pentraxin 2 therapy resulted in a slower decline in lung function in patients with idiopathic pulmonary fibrosis.
A Sarcoidosis Diagnostic Score tool was developed by comparing data from individuals with biopsy-confirmed sarcoidosis with that of individuals who did not have sarcoidosis.
The frequency of migraine and sarcoidosis comorbidity was examined in a cohort study.
Experts in interstitial lung disease identified 18 items of importance for diagnosing chronic hypersensitivity pneumonitis.
Treatment for gastroesophageal reflux significantly reduced mortality in idiopathic pulmonary fibrosis and improved transplant-free survival.
Researchers identified independent predictors of short-term dermatomyositis- or polymyositis-related interstitial lung disease mortality.
RP5063 is a new chemical entity with a novel mechanism of multimodal modulation of serotonin and dopamine signaling pathways.
Several patients were treated for idiopathic pulmonary fibrosis were identified as dental personnel.
After being treated for pyelonephritis and discharged to a nursing facility, a 67-year-old woman presents to the emergency department with shortness of breath.
In patients with acute respiratory distress syndrome, cisatracurium does not improve mortality when compared with vecuronium, but is associated with improvements in other outcomes.
A significant enrichment of potential pathogens occurred in patients who smoked and who were admitted to the hospital for severe trauma.
Translational research has increased the understanding of the mechanisms of ventilator-induced lung injury.
Treatments for acute respiratory distress syndrome that have less evidence to support their use have been overused by clinicians.